

# Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

NCT05758493

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Oregon Health and Science University
Enrollment	150 participants

## Key Eligibility Criteria

---

### Inclusion (2)

- Subjects will at least have one of the following conditions: systemic amyloidosis with known organ involvement, carrier of a known pathogenic mutation in the transthyretin gene, multiple myeloma, and monoclonal gammopathy of undetermined significance
- Patient willing to consent for the study and undergo the study procedures.

### Exclusion (4)

- Has severe claustrophobia or any medical condition that would prevent completion of the imaging protocol
- Has a known allergy to potassium iodide treatment or to gadolinium.
- Patients on dialysis or those with eGFR  $<30$  cc/min/1.73 m<sup>2</sup> will be excluded from undergoing gadolinium-enhanced cardiac MRI.
- Has received heparin or heparin analogs (e.g., enoxaparin, dalteparin, fondaparinux) within 7 days prior to 124I-Evuzumitide administration

## Locations (1 total)

---

Oregon Health & Science University, Portland, Oregon, United States